Telomere biology in giant cell tumour of bone

Journal of Pathology

Volumn 214, Issue 5, 2008, Pages 555-563

  Forsyth, R G ^a   De Boeck, G ^a   Bekaert, S ^b   De Meyer, T ^b   Taminiau, A H M ^c   Uyttendaele, D ^a   Roels, H ^a   Praet, M M ^a   Hogendoorn, P C W ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

APB; Bone neoplasm; Giant cell tumour; hTERT; Nucleolin; PML; Telomerase; Telomere; Telomere maintenance; Telomeric association

Indexed keywords

NUCLEOLIN; PROMYELOCYTIC LEUKEMIA PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; ARTICLE; BONE TUMOR; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GIANT CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; MOLECULAR BIOLOGY; MONONUCLEAR CELL; PATHOGENESIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TELOMERE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

ADOLESCENT; ADULT; BONE NEOPLASMS; FEMALE; GIANT CELL TUMORS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OSTEOCLASTS; PHOSPHOPROTEINS; RNA-BINDING PROTEINS; TELOMERASE; TELOMERE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 41649102820     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2301     Document Type: Article

References (34)

1. Reid R, Banerjee SS, Sciot R. Giant cell tumour. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, Fletcher CD, Unni KK, Mertens F (eds). IARC Press: Lyon, 2002; 310-312.
2. Sanerkin NG. Malignancy, aggressiveness, and recurrence in giant cell tumor of bone. Cancer 1980;46:1641-1649.
3. Goldenberg RR, Campbell CJ, Bonfiglio M. Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. J Bone Joint Surg Am 1970;52:619-664.
4. Katz E, Nyska M, Okon E, Zajicek G, Robin G. Growth rate analysis of lung metastases from histologically benign giant cell tumor of bone. Cancer 1987;59:1831-1836.
5. Bertoni F, Present D, Enneking WF. Giant-cell tumor of bone with pulmonary metastases. J Bone Joint Surg Am 1985;67:890-900.
6. Zheng MH, Robbins P, Xu J, Huang L, Wood DJ, Papadimitriou JM. The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001;16:297- 307.
7. Schwartz HS, Eskew JD, Butler MG. Clonality studies in giant cell tumor of bone. J Orthop Res 2002;20:387-390.
8. Scheiner M, Hedges L, Schwartz HS, Butler MG. Lack of microsatellite instability in giant cell tumor of bone. Cancer Genet Cytogenet 1996;88:35-38.
9. Rao UN, Goodman M, Chung WW, Swalski P, Pal R, Finkelstein S. Molecular analysis of primary and recurrent giant cell tumors of bone. Cancer Genet Cytogenet 2005;158:126-136.
10. Bridge JA, Mouron BJ, Neff JR, Bhatia PS. Significance of chromosomal abnormalities in a malignant giant cell tumor of bone. Cancer Genet Cytogenet 1991;57:87-92.
11. Schwartz HS, Butler MG, Jenkins RB, Miller DA, Moses HL. Telomeric associations and consistent growth factor overexpression detected in giant cell tumor of bone. Cancer Genet Cytogenet 1991;56:263-276.
12. Bridge JA, Neff JR, Mouron BJ. Giant cell tumor of bone. Chromosomal analysis of 48 specimens and review of the literature. Cancer Genet Cytogenet 1992;58:2-13.
13. Sciot R, Dorfman H, Brys P, Dal Cin P, De Wever I, Fletcher CD, et al. Cytogenetic-morphologic correlations in aneurysmal bone cyst, giant cell tumor of bone and combined lesions. A report from the CHAMP study group. Mod Pathol 2000;13:1206-1210.
14. Bridge JA, Neff JR, Bathia PS, Sanger WG, Murphey MD. Cytogenetic findings and biologic behavior of giant cell tumors of bone. Cancer 1990;65:2697-2703.
15. Sawyer JR, Goosen LS, Binz RL, Swanson CM, Nicholas RW. Evidence for telomeric fusions as a mechanism for recurring structural aberrations of chromosome 11 in giant cell tumor of bone. Cancer Genet Cytogenet 2005;159:32-36.
16. Bekaert S, Van Pottelbergh I, De Meyer T, Zmierczak H, Kaufman JM, Van Oostveldt P, et al. Telomere length versus hormonal and bone mineral status in healthy elderly men. Mech Ageing Dev 2005;126:1115-1122.
17. Yeager TR, Neumann AA, Englezou A, Huschtscha LI. Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999;59:4175-4179.
18. Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, et al. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci 2006;119:2797-2806.
19. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yaeger TR, Robinson RA, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005;11:217-225.
20. Annels NE, Da Costa CE, Prins FA, Willemze A, Hogendoorn PC, Egeler RM. Abberant chemokine receptor expression and chemokine production by Langerhans cells underlie the pathogenesis of Langerhans cell histiocytosis. J Exp Med 2003;197:1385-1390.
21. Hameetman L, David G, Yavas A, White SJ, Taminiau AHM, Cleton-Jansen AM, et al. Decreased EXT expression and intracellular accumulation of HSPG in osteochondromas and peripheral chondrosarcomas. J Pathol 2007;211:399-409.
22. Schwartz HS, Juliao SF, Sciadini MF, Miller LK, Butler MG. Telomerase activity and oncogenesis in giant cell tumor of bone. Cancer 1995;75:1094-1099.
23. Kyo S, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, et al. Significance of immunological detection of human telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase. Am J Pathol 2003;163:859-867.
24. Dickinson LA, Kohwi-Shigematsu T. Nucleolin is a matrix attachment region DNA-binding protein that specifically recognizes a region with high base-unpairing potential. Mol Cell Biol 1995;15:456-465.
25. Khurts S, Masutomi K, Delgermaa L, Arai K, Oishi N, Mizuno H, et al. Nucleolin interacts with telomerase. J Biol Chem 2004;279:51508-51515.
26. Pollice A, Zibella MP, Bilaud T, Laroche T, Pulitzer JF, Gilson E. In vitro binding of nucleolin to double-stranded telomeric DNA. Biochem Biophys Res Commun 2000;268:909-915.
27. Fu W, Begley JG, Killen MW, Mattson MP. Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 1999;274:7264-7271.
28. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Am 1996;274:92-97.
29. Schwartz HS, Dahir GA, Butler MG. Telomere reduction in giant cell tumor of bone and with aging. Cancer Genet Cytogenet 1993;71:132-138.
30. Karlseder J. Telomeric proteins: clearing the way for the replication fork. Nature Struct Mol Biol 2006;13:386-387.
31. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998;92:401-413.
32. Ishikawa F, Matunis MJ, Dreyfuss G, Cech TR. Nuclear proteins that bind the pre-mRNA 3′ splice site sequence r(UUAG/G) and the human telomeric DNA sequence d(TTAGGG)n. Mol Cell Biol 1993;13:4301-4310.
33. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 2002;99:12606-12611.
34. Volpi A, Bravaccini S, Medri L, Cerasoli S, Gaudio M, Amadori D. Usefulness of immunological detection of the human telomerase reverse transcriptase. Cell Oncol 2005;27:347-353.